A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab

Trial Profile

A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Motolimod (Primary) ; Cetuximab; Nivolumab
  • Indications Head and neck cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors VentiRx Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2017 Results (n=14) assessing the effect of neoadjuvant cetuximab plus motolimod, published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 06 Jan 2016 New drug 'Nivolumab' has been added in the study and also 1 treatment arm has been added as reported by ClinicalTrials.gov record.
    • 06 Jan 2016 Planned number of patients changed from 15 to 24 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top